<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30143449</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>25</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1938-0666</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Jul</Month>                        <Day>29</Day>                    </PubDate>                </JournalIssue>                <Title>Clinical breast cancer</Title>                <ISOAbbreviation>Clin. Breast Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>MicroRNAs 182 and 375 Sera Expression as Prognostic Biochemical Markers in Breast Cancer.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">S1526-8209(18)30232-5</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clbc.2018.07.020</ELocationID>            <Abstract>                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Breast cancer (BC) is the most common malignancy among women; supporting the need for identification of novel prognostic biomarkers, circulating microRNAs (miRNAs) could serve as such in various cancers. The aim of this study was to explore the association between miRNAs 182 and 375 with BC stages and its receptors, based on their expression using real time PCR.</AbstractText>                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Detailed medical history was taken and blood samples were withdrawn from 80 female subjects divided over the studied groups. Patients ranged in age from 24 to 80 years and were classified as follows: group I included 10 noncancerous postmenopausal control subjects; group II included 32 postmenopausal patients with BC; group III included 10 noncancerous premenopausal control subjects; group IV included 24 premenopausal patients with BC; and group V included 6 patients with benign breast tumors.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">miRNA 182 expression was significantly higher in group II, group IV, and group V (3.36 ± 0.14, 2.52 ± 0.34, and 4.93 ± 0.3,9 respectively); miRNA 375 expression was significantly higher in group II, group IV, and group V (4.41 ± 0.40, 3.12 ± 0.35, and 11.28 ± 2.37, respectively) (P &lt; .05). Both miRNAs were significantly associated with each other and with receptors used for the prognosis of BC even after multiple regression analysis.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Accordingly, miRNAs 182 and 375 could be potential noninvasive markers used for the follow up of BC patients.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Inc. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Ali</LastName>                    <ForeName>Ola S</ForeName>                    <Initials>OS</Initials>                    <AffiliationInfo>                        <Affiliation>Biochemistry Department, Faculty of Pharmacy (Girls), Al Azhar University, Nasr City, Cairo, Egypt.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shabayek</LastName>                    <ForeName>Marwa I</ForeName>                    <Initials>MI</Initials>                    <AffiliationInfo>                        <Affiliation>Biochemistry Department, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University, Fifth Settlement, Cairo, Egypt.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Seleem</LastName>                    <ForeName>Mae M</ForeName>                    <Initials>MM</Initials>                    <AffiliationInfo>                        <Affiliation>Biochemistry Department, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University, Fifth Settlement, Cairo, Egypt. Electronic address: mseleem@fue.edu.eg.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Abdellateif</LastName>                    <ForeName>Heba G</ForeName>                    <Initials>HG</Initials>                    <AffiliationInfo>                        <Affiliation>Biochemistry Department, Faculty of Pharmacy (Girls), Al Azhar University, Nasr City, Cairo, Egypt.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Makhlouf</LastName>                    <ForeName>Dalia O</ForeName>                    <Initials>DO</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Pharmacy Department, Childrens Cancer Hospital (57357), El-Sayeda Zainab, Cairo, Egypt.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>29</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Clin Breast Cancer</MedlineTA>            <NlmUniqueID>100898731</NlmUniqueID>            <ISSNLinking>1526-8209</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Circulating miRNAs</Keyword>            <Keyword MajorTopicYN="N">Diagnosis</Keyword>            <Keyword MajorTopicYN="N">Gene expression</Keyword>            <Keyword MajorTopicYN="N">miRNA 182</Keyword>            <Keyword MajorTopicYN="N">miRNA 375</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30143449</ArticleId>            <ArticleId IdType="pii">S1526-8209(18)30232-5</ArticleId>            <ArticleId IdType="doi">10.1016/j.clbc.2018.07.020</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>